Valeant Pharmaceuticals International, Inc. (VRX) Earns Hold Rating from Deutsche Bank AG

Doris Richards
October 13, 2017

Also, the Hold rating count is 13 as of 10/12/17. The stock closing price is now trading downward to its 50 day moving average with change of -2.54%, tumbled to its 20 day moving average with figure of -2.61% and above its 200 day moving average with value 1.19%. Finally, Cantor Fitzgerald set a $23.00 price objective on Valeant Pharmaceuticals International and gave the company a "buy" rating in a report on Wednesday, August 16th. The shares price has directed -39.05% toward a lower level throughout a year ago and swapped -1.98% toward a weak spot during past one month. The count of Hold ratings in that period was 13. Finally, Guggenheim started coverage on Valeant Pharmaceuticals International in a research report on Saturday, June 17th. Jefferies maintained it with "Buy" rating and $172 target in Monday, November 2 report.

Analyst's mean target price for DEPO is $10.5 while analysts mean suggestion is 3. Bessemer Gp stated it has 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since October 12, 2016 and is downtrending. The company has market cap of $4.97 billion. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $24.30. The company's 50-day moving average price is $14.02 and its 200 day moving average price is $13.51. (NYSE:VRX) are -5.08%; -1.98% for the month; -19.78% for the last quarter; 45.89% for the past six-months; and -39.05% for the last 12 months. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.97 by $0.08.

Valeant Pharmaceuticals International, a pharmaceutical and medical device company. The company had revenue of $2.23 billion for the quarter, compared to analysts' expectations of $2.23 billion. The Capstone Investment Advisors Llc holds 46,800 shares with $808,000 value, up from 25,000 last quarter. During the same period in the prior year, the firm earned ($1.08) earnings per share.

Valeant Pharmaceuticals International, Inc. has a consensus hold rating from 21 Wall Street analysts, and the number of shares now sold short amount to at least 11.27% of shares outstanding. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & global copyright and trademark legislation. The legal version of this story can be viewed at IBC downgraded the stock to "Sector Perform" rating in Tuesday, October 20 report. The stock's average target of $37 is -9.20% below today's ($40.75) share price. Following the completion of the transaction, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The transaction was disclosed in a filing with the SEC, which is available at this link. World Asset Management Inc now owns 21,502 shares of the specialty pharmaceutical company's stock worth $237,000 after buying an additional 328 shares during the period.

Institutional investors have recently modified their holdings of the business. Cambridge Advisors Inc. now owns 12,650 shares of the specialty pharmaceutical company's stock worth $140,000 after buying an additional 75 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Valeant Pharmaceuticals International by 33.7% in the first quarter. Following the purchase, the director now owns 70,572 shares of the company's stock, valued at approximately $980,950.80. Janney Montgomery Scott LLC raised its stake in shares of Valeant Pharmaceuticals Intl by 4.5% in the first quarter. Canada Pension Plan Investment Board grew its holdings in shares of Valeant Pharmaceuticals International by 24,953.6% in the 2nd quarter.

Market capitalization is just a fancy declare for a comprehensible concept: it is the market value of a company's outstanding shares.

Other reports by Iphone Fresh

Discuss This Article